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Prestes PR, Marques FZ, Lopez-Campos G, Lewandowski P, 
Delbridge LM, Charchar FJ, Harrap SB. Involvement of human 
monogenic cardiomyopathy genes in experimental polygenic cardiac 
hypertrophy. Physiol Genomics 50: 000 – 000, 2018. First   published 
May 18, 2018; doi:10.1152/physiolgenomics.00143.2017.—Hyper- 
trophic cardiomyopathy thickens heart muscles, reducing functional- 
ity and increasing risk of cardiac disease and morbidity. Genetic 
factors are involved, but their contribution is poorly understood. We 
used the hypertrophic heart rat (HHR), a unique normotensive poly- 
genic model of cardiac hypertrophy and heart failure, to investigate 
the role of genes associated with monogenic human cardiomyopathy. 
We selected 42 genes involved in monogenic human cardiomyopa- 
thies to study: 1) DNA variants, by sequencing the whole genome of 
13-wk-old HHR and age-matched normal heart rat (NHR), its genetic 
control strain; 2) mRNA expression, by targeted RNA-sequencing in 
left ventricles of HHR and NHR at 5 ages (2 days old and 4, 13, 33, 
and 50 wk old) compared with human idiopathic dilated data; and 3) 
microRNA expression, with rat microRNA microarrays in left ven- 
tricles of 2-day-old HHR and age-matched NHR. We also investigated 
experimentally validated microRNA-mRNA interactions. Whole-ge- 
nome sequencing revealed unique variants mostly located in noncod- 
ing regions of HHR and NHR. We found 29 genes differentially 
expressed in at least 1 age. Genes encoding desmoglein 2 (Dsg2) and 
transthyretin (Ttr) were significantly differentially expressed at all 
ages in the HHR, but only Ttr was also differentially expressed in 
human idiopathic cardiomyopathy. Lastly, only two microRNAs dif- 
ferentially expressed in the HHR were present in our comparison of 
validated microRNA-mRNA interactions. These two microRNAs in- 
teract with five of the genes studied. Our study shows that genes 
involved in monogenic forms of human cardiomyopathies may also 
influence polygenic forms of the  disease. 
cardiac hypertrophy; cardiomyopathy; DNA sequencing; gene expres- 
sion; microRNA 
 
 
INTRODUCTION 
Cardiovascular disease (CVD) is the main cause of death 
and morbidity worldwide, having killed ~17.5 million   people 
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in 2012 (23, 37). Both genetic and environmental factors 
contribute to CVD. The most common genetic contributions 
are considered to be polygenic, although the exact number and 
nature of genes involved has been difficult to determine as new 
genes are yet to be identified with the advancement of tech- 
nology (16). However, less common monogenic causes of 
cardiac hypertrophy (CH) have been well characterized in 
terms of the causative DNA variants and pathophysiology (10, 
26). Variation of the expression of genes involved in mono- 
genic CH might provide clues to the causes of polygenic 
etiology of CH. 
Hypertrophic cardiomyopathy (HCM) is the most common 
inherited form of CVD, affecting 1 in 500 adults, and is the 
major cause of heart failure and sudden death in young people 
(21, 25, 26). The condition is characterized by the asymmetric 
thickening of the cardiac wall, heart failure, and risk of sudden 
death. A variety of mutations in genes coding sarcomere and 
cardiac filament proteins account for over 88% of familial 
HCM (5, 26, 31). Mutations in two genes that encode myosin 
heavy chain 7 (MYH7) and cardiac myosin binding protein C 
(MYBPC3) are the most common causes of monogenic HCM 
(31, 39). Familial dilated cardiomyopathies form another im- 
portant group of monogenic CVD characterized by CH and 
heart failure for which mutations in genes encoding sarcomeric 
proteins account for almost half of the known forms   (15). 
The study of genes involved in monogenic hypertrophy and 
failure have led to an understanding of disease mechanisms and 
might also provide explanations for more common polygenic 
forms of heart failure. 
We have developed and characterized the hypertrophic 
heart rat (HHR), a unique polygenic normotensive model of 
spontaneous ventricular hypertrophy, cardiac failure, and 
premature death (13). Compared with their genetic control 
strain, the normal heart rat (NHR), HHR begin life with fewer 
cardiomyocytes that develop cellular hypertrophy leading to  
cardiac enlargement and heart failure   (29). 
Our aim was to study genes previously associated with 
human monogenic forms of dilated and hypertrophic cardio- 
myopathies in the polygenic etiology of CH in the HHR. We 
combined  analyses  of  RNA  expression  and  DNA sequence 
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variation to identify those genes that might be of importance in 
the polygenic setting. 
 
MATERIALS  AND METHODS 
 
Sample collection. The HHR and NHR strains have been de- 
scribed in detail elsewhere (13). Two-day-old HHR and NHR (n = 
8 HHR, n = 9 NHR) were euthanized by decapitation. At 4 (n = 
10 HHR, n  = 10  NHR), 13  (n  = 10  HHR, n  = 11  NHR), 33  
(n = 7 HHR, n = 9 NHR), and 50 (n = 12 HHR, n = 10 NHR) 
wk of age, rats were euthanized using a lethal dose of pentobar- 
bitone (Lethobarb). Hearts were removed and left ventricles (LVs) 
were immediately dissected from atria. Cardiac weight indexes 
(mg/g) were calculated as the total heart weight (mg) relative to 
total body weight (g)  of  each animal (Ref. 28  and  Fig.  1). 
The 5 age groups investigated represent different developmental 
stages in their life: prior to hypertrophy (2-day-old), during the 
development of hypertrophy (4 wk), early hypertrophy (13 wk), 
established hypertrophy (33 wk), and hypertrophy complicated by 
heart failure (50 wk-old). This study was approved by the Animal 
Ethics Committees of the University of Melbourne and Deakin Uni- 
versity and ratified at Federation University  Australia. 
DNA and RNA extraction. DNA from LV was extracted using 
PureLink Genomic Extraction kit (Thermo Fisher Scientific). RNA 
from LV was extracted using miRNeasy kit (Qiagen). DNA was 
quantified by spectrophotometry using NanoDrop 2000, and RNA was 
quantified by fluorescence using Qubit 3.0 Fluorometer and the RNA 
high sensitivity assay kit (Thermo Fisher  Scientific). 
Genes investigated. For these focused studies, we selected 42 genes 
(Table 1) involved in monogenic forms of familial cardiomyopathies 
(5, 15, 31, 39). Physiologically, most of these genes are involved in 
growth and contractility, regulation of mechanical stress, calcium 
channels, and a variety of muscle development pathways, mainly for 
cardiac filaments and sarcomere assembly (5,  31). 
DNA sequence variants in HHR were identified according to 
methods detailed previously (30). Briefly, we sequenced the whole 
genome of 1 male 13-wk-old NHR and 1 age-matched HHR. Variants 
were analyzed according to Genome Analysis Toolkit best practices 
(35), and functional annotation was performed using SnpEff software 
(4). Results were stored in a database developed in house, and then we 
identified unique single nucleotide polymorphisms (SNPs) and inser- 
tions/deletions (InDels) in the NHR and HHR   (30). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. The hypertrophic heart rat (HHR) has an enlarged heart when compared 
with its genetic control, the normal heart rat (NHR). Cardiac weight index 
(mg/g) of HHR is represented as a percentage difference to NHR (normalized 
to 100%) at 2 days old and 4, 13, 33, and 50 wk old (n = 7–12 per group per 
 
mRNA expression of the genes listed in Table 1 was measured 
using Targeted RNA Expression custom panel in the MiSeq Desktop 
sequencer (Illumina) and analyzed using MSR: Targeted RNA 
v2.4.60.8  on  Illumina  BaseSpace.  False  discovery  rate  was  set as 
<0.1. 
microRNA (miRNA) arrays were conducted using the Agilent rat 
microRNA microarray kit 16.0 in LVs of 2-day-old male HHR and 
age-matched NHR (n = 4/group). The data obtained have been 
deposited in the National Center for Biotechnology Information Gene 
Expression Omnibus (GEO) database with series accession number 
GSE38710. Differentially expressed miRNAs were identified using 
Partek Genomics Suite v6.6 with false discovery rate set as <0.05. 
In silico investigations. We combined in silico approaches to 
explore a link between gene expression and DNA sequencing data 
from the HHR and NHR and human studies available   online. 
We investigated the possibility that miRNAs might be involved in 
regulating mRNA expression pre- and posttranscriptionally using 
three algorithms individually [miRWalk 2.0 (7, 8), miRanda (3), and 
TargetScan (11)] as a comparative platform to predict possible 
miRNA binding sites within the sequence in and around each gene of 
interest. We also used miRWalk 2.0 to investigate experimentally 
validated miRNA-mRNA interactions and evaluate which miRNAs 
targeted the genes under  investigation. 
As DNA methylation can modulate gene expression by com- 
pacting DNA sequences, we investigated if any of the DNA sites 
were differentially methylated in CVD using the Disease Meth 
database  2.0 (38). 
Gene expression in human hearts. We also investigated the mRNA 
expression of the genes listed identified in HHR in human cardiac 
samples from the data set “heart failure arising from different etiol- 
ogies” in the repository GEO reference series GSE1145 (2, 9) (n = 11 
control hearts and n = 15 idiopathic dilated hearts). We then deter- 
mined the expression of the genes investigated using the GEO tool 
GEO2R. 
 
RESULTS 
 
DNA sequence analyses. DNA sequencing in and around the 
42 genes of interest revealed greater number of unique DNA 
variants discovered in the HHR (compared with the rat refer- 
ence genome), with 851 SNPs and 491 InDels as opposed to 
383 SNPs and 316 InDels in the NHR (Table 1). We found no 
evidence of DNA sequence variation in six genes in the NHR 
(namely Csrp3, Emd, Gla, Mylk2, Pln, and Taz) and three 
genes in the HHR (Emd, Myoz2, and Tpm1, Table   1). 
In both the HHR and NHR, most unique variants were 
located in intergenic or intronic regions. However, we found 11 
unique synonymous SNPs in exonic regions in the HHR and 2 
in the NHR. These SNPs were located in genes encoding 
actinin alpha 2 (Actn2), desmin (Des), ryanodine receptor 2 
(Ryr2), troponin T type 2 (Tnnt2), and vinculin (Vcl) in the 
HHR and Ryr2 and Vcl in the NHR. Interestingly, only one 
unique nonsynonymous missense variant (gGt>gTt) in an 
exonic region was found in the Vcl gene in the NHR, changing 
the amino acid from glycine to  valine. 
Cardiac RNA expression analyses. The relative fold changes 
in mRNA expression in the HHR relative to NHR were never 
greater than fourfold for any of the 42 genes under investiga- 
tion. We found that 29 of the 42 genes showed significant 
differential expression for at least 1 age (Figs. 2, 3, and 4). 
Genes differentially expressed were not consistent through- 
out the age groups, possibly reflecting developmental stage- 
specific  regulation.  At  2  days  old,  only  four  genes     were 
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differentially expressed (Fig. 2A). In contrast, at 4 wk of    age, 
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Table 1.      Variants found in each gene investigated unique to each strain classified according to type 
Frequency in Patients, % Rat Genome HHR NHR 
 
AQ: 17 Gene ID Gene Name Hypertrophic Dilated  Chr Location Strand SNP InDel SNP InDel 
 Abcc9 ATP-binding cassette, subfamily C member  9 n/d 0.6  4 241,019,980–241,139,051   4 10 2 9 
 Actc1 Cardiac actin alpha 1 <1 Rare  3 112,080,853–112,086,389   3 2 1 1 
 Actn2 Actinin alpha 2 Rare 0.9  17 68,050,946–68,143,522   61 42 58 39 
 Ankrd1 Ankyrin repeat domain 1 Rare 1.9  1 262,038,137–262,046,691 + None 5 2 2 
 Casq2 Calsequestrin 2 Rare n/d  2 223,945,611–224,001,893 + 11 8 5 12 
 Cav3 Caveolin 3 0.6 n/d  4 207,683,202–207,699,176 + None 2 None 1 
 Cryab Crystallin, alpha B n/d 0.7  8 53,776,100–53,779,780 + 3 6 2 8 
 Csrp3 Cysteine and glycine-rich protein  3 Rare 0.3  1 105,206,459–105,225,635   1 1 None None 
 Ctf1 Cardiotrophin 1 n/d n/d  1 206,186,511–206,191,930 + 2 3 None 3 
 Des Desmin n/d 0.3–2.1  9 82,325,835–82,333,549 + 34 7 None 1 
 Dsc2 Desmocollin 2 n/d n/d  18 11,625,847–11,658,036   9 4 2 3 
 Dsg2 Desmoglein 2 n/d 2.3  18 15,353,348–15,411,825   5 3 24 4 
 Emd Emerin n/d n/d  1 152,192,993–152,196,004   None None None None 
 Fhl2 Four and a half LIM domains  2 n/d 2.1  9 49,591,185–49,664,022   1 5 None 3 
 Gla Galactosidase, alpha 1–2 in men n/d  X 105,295,029–105,306,686   None 1 None None 
 Jup Junction plakoglobin n/d n/d  10 88,073,764–88,100,700   1 10 1 6 
 Lama4 Laminin, alpha 4 n/d 1.1  20 45,786,892–45,926,468 + 37 24 101 17 
 Lamp2 Lysosomal-associated membrane protein 2 Rare n/d  X 124,809,053–124,852,509   2 4 1 3 
 Lmna Lamin A/C n/d 6–7.5  2 207,245,237–207,265,928   24 11 3 11 
 Mybpc3 Myosin binding protein C 20–42 0.2–4  3 86,649,264–86,667,484 + None 3 None 3 
 Myh6 Myosin heavy chain 6 Rare 4.3  15 37,492,599–37,516,786   1 4 None 3 
 Myh7 Myosin heavy chain 7 20–40 4.2–6.3  15 37,512,803–37,544,317   2 None None 1 
 Myl2 Myosin light chain 2 <5 n/d  12 41,831,137–41,835,806   6 13 5 7 
 Myl3 Myosin light chain 3 1–2 n/d  8 118,370,030–118,376,218 + None 4 3 4 
 Mylk2 Myosin light chain kinase  2 Rare n/d  3 154,789,177–154,800,843 + None 1 None None 
 Myoz2 Myozenin 2 Rare n/d  2 246,542,267–246,569,008   None None 2 None 
 Nexn Nexilin n/d 1  2 276,129,684–276,161,434   2 5 2 2 
 Pkp2 Plakophilin 2 n/d n/d  11 91,966,047–92,031,277   2 4 2 4 
 Pln Phospholamban Rare Rare  20 36,390,879–36,400,626 + 1 None None None 
 Prkag2 Protein kinase, AMP-activated, non-catalytic           
  subunit gamma 2 <1 n/d  4 6,577,007–6,816,813 + 2 4 None 5 
 Psen2 Presenilin 2 n/d 1  13 103,521,460–103,547,174   1 0 2 2 
 Rbm20 RNA binding motif protein  20 n/d 1.9  1 281,783,646–282,003,053 + 12 21 3 12 
 Ryr2 Ryanodine receptor 2 Rare n/d  17 67,285,205–67,704,766   518 218 122 106 
 Sgcd Sarcoglycan delta n/d Rare  10 31,878,904–32,285,036   26 34 15 24 
 Taz Tafazzin n/d n/d  1 152,161,153–152,169,569   1 None None None 
 Tmem43 Transmembrane protein 43 n/d n/d  4 187,412,090–187,427,232   3 2 2 1 
 Tnnc1 Troponin C type 1 Rare 0.4  16 7,220,777–7,223,730 + 0 0 0 0 
 Tnnt2 Troponin T type 2 3–10 2.9  13 57,711,369–57,729,182 + 48 13 3 4 
 Tpm1 Tropomyosin 1 <5 0.6–1.9  8 77,147,580–77,174,392   None None None 2 
 Ttn Titin Rare 14.1–20  3 70,138,896–70,408,647   24 12 6 10 
 Ttr Transthyretin 1–10 n/d  18 15,307,563–15,316,780   None 1 8 1 
 Vcl Vinculin Rare Rare  15 3,433,521–3,522,441   4 4 6 2 
 Total        851 491 383 316 
Chr, chromosome; HHR, hypertrophic heart rat; ID, identification; InDel, insertion/deletion; n/d, not described; NHR, normal heart rat; SNP, single nucleotide 
polymorphism. 
 
we observed 50% of genes differentially expressed, the highest 
prevalence of all the age groups (Fig. 2B). Most of the 
differences at this age presented increased expression. For 
some genes (such as Gla, Jup, Lamp2, and Pln) differential 
expression was evident only at 4 wk of age. The differential 
expression of other genes (such as Actc1, Cav3, and Fhl2) 
became first evident at 4 wk of age and then persisted through- 
out adulthood. Differences in the expression of other genes 
(such as Tnnt2, Myoz2, and Myl3) appeared at 4 wk of age but 
disappeared in later adulthood. Still other genes (such as 
Ankrd1) did not show differential expression until later adult- 
hood (Figs. 2, 3, and  4). 
Two genes, those encoding desmoglein 2 (Dsg2) and tran- 
sthyretin (Ttr) were significantly differentially expressed at all 
ages in the HHR compared with NHR. Dsg2 was underex- 
pressed in the hearts of HHR at all ages sampled, whereas Ttr 
was significantly downregulated at day 2 in the neonatal period 
but significantly upregulated at all subsequent ages correspond- 
ing to the development of cardiomyocyte hypertrophy (Fig. 2). 
Ttr also showed greater expression in adult human idiopathic 
cardiomyopathy (Fig. 4). 
The analysis of human idiopathic cardiomyopathy revealed 
that 16 orthologous genes differentially expressed of the 42 
genes investigated. We found only 9 of those 16 genes were 
also differentially expressed in at least 1 rat   age. 
Predicted miRNA binding sites. We also predicted possible 
miRNA binding sites within and around each gene region. 
Potentially there are over 220,000 miRNA binding sites in the 
gene coding regions alone and almost 54,000 in the promoter 
regions (Table 2). However, our comparison of validated T2 
miRNA-mRNA interactions  to  miRNAs  differentially  ex- 
pressed in HHR compared with NHR in our microarray data  
found two miRNAs (miR-34a-5p and miR-17–5p) upregulated 
in the HHR (Table 3). Interestingly, those two miRNAs inter- T3 
act with 5 of the genes investigated, plakophilin 2 (Pkp2), RNA 
binding  motif  protein  20  (Rbm20),  Ryr2,  tropomyosin  1 
(Tpm1), and Vcl (14, 19, 24). Although not statistically signif- 
icant, the gene expression of Pkp2, Ryr2, Tpm1, and Vcl is 
Physiol Genomics • doi:10.1152/physiolgenomics.00143.2017 • www.physiolgenomics.org 
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Fig. 2. Heart mRNA expression of genes differentially expressed in at least one age group. There are 4 and 21 genes differentially expressed in neonatal (A) and 
4-wk-old (B) hypertrophic heart rats (HHR), respectively. HHR fold change relative to normal heart rat (NHR) is shown. Genes not differentially expressed are 
shown in open boxes. *P < 0.05; **P < 0.01; ***P < 0.001. 
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AQ:9 
downregulated in 2-day-old HHR (fold change = 0.93, 0.95, 
0.89, and 0.88, respectively). 
Other analyses. Scans of published genome-wide associa- 
tion studies [GWAS; using GWASdb v2 (22)] data also indi- 
cated the presence of SNPs found in the 42 genes investigated 
that are associated with CVD traits in humans (Table   4). 
Surprisingly no methylation profiles have been reported in 
human heart-related diseases for any of the genes in our data 
set. 
DISCUSSION 
The HHR and their NHR genetic control are derived from 
the spontaneously hypertensive rat and Fisher 344 rat and 
provide a unique model of left ventricular hypertrophy inde- 
pendent of high blood pressure and heart failure. Although 
HHR and NHR have a polygenic background, it is not unrea- 
sonable to presume that genes best known for their major 
mutations causing human cardiac and failure might also en- 
compass DNA variants with a more subtle quantitative impact 
on cardiac structure and function. Here we sought to determine 
whether any of the 42 genes implicated in Mendelian human 
hypertrophic and dilated cardiomyopathies might also be rel- 
evant to the polygenic hypertrophy of HHR, either as DNA 
sequence variants or abnormal gene expression patterns. We 
had the advantage with our life course approach to examine 
also the ontogeny of the expressions of these genes and their 
relationships with the developmental stages of hypertrophy in 
the HHR. 
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Fig. 3. Heart mRNA expression of genes differentially expressed in at least one age group. There are 14 and 13 genes differentially expressed in 13-wk-old (A) 
and 33-wk-old (B) hypertrophic heart rats (HHR), respectively. HHR fold change relative to normal heart rat (NHR) is shown. Genes not differentially expressed 
are shown in open boxes. *P < 0.05; **P < 0.01; ***P < 0.001. 
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Fig. 4. Heart mRNA expression of genes differentially expressed in at least one age group. There are 10 and 9 genes differentially expressed in 50-wk-old 
hypertrophic heart rats (HHR; A) and human idiopathic dilated cardiomyopathy (DCM; B), respectively. HHR fold change relative to normal heart rat (NHR)    
is shown. DCM patient fold change relative to healthy is shown in humans. Genes not differentially expressed are shown in open boxes. *P < 0.05; **P < 0.01; 
***P < 0.001. 
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Molecular genetic studies have identified over 1,400 muta- 
tions responsible for inherited cardiomyopathies, and genetic 
testing is offered to identify genetic causes in families or assess 
family members at risk (26, 34). However, emerging data 
suggest that compound mutations have an additive role causing 
a gene dosage effect influencing the severity and progression of 
HCM (17, 20, 27). Such interactions at the level of monogenic 
cardiomyopathic disease provide general support for the hy- 
pothesis that interaction between other DNA variants in the 
same genes might influence polygenic  CH. 
Among the sequence variants identified in our sequencing 
analyses, we found 11 synonymous SNPs in exonic regions in 
the HHR and 1 nonsynonymous SNP in the NHR. It is well 
established that nonsynonymous mutations may impact amino 
acid sequences and therefore human health (18). However, 
synonymous variants that had previously been regarded as 
“silent” mutations and thought to have no effect on disease 
phenotype have also been reported to cause changes in protein- 
protein interactions. Importantly, studies suggest that these 
synonymous mutations contribute to human disease risk and 
other complex traits (32). The synonymous variants we dis- 
covered (Table 1) might result in changes in protein-protein 
interactions and explain changes in gene expression (Fig. 1) 
because of imbalanced availability of tRNA caused by codon 
bias (12). 
Interestingly, HHR are born with smaller and fewer cardio- 
myocytes than NHR. We believe that this reduced endowment 
is important for the subsequent development of cardiomyocyte 
hypertrophy, which becomes evident in early adolescence (4 
wk, Fig. 1), when increased pressure and volume loads in the 
growing animals place proportionately greater stress on the 
fewer individual myocytes (29). By 13 wk of age, both cardiac 
and cardiomyocyte hypertrophy are established (Ref. 13 and 
Fig. 1), but in the end this is counterproductive, as the enlarged 
cells do not function efficiently and gradually deteriorate, 
leading to heart failure (evident as early as 30 wk of age)   and 
premature death (toward 50 wk of age) (13, 29). These patho- 
physiological phenotypic changes can provide context for the 
developmental stage-specific changes in gene expression we 
observed. 
Our analysis of gene expression showed that at 2 days old, 
when HHR hearts are smaller than NHR (29), the genes 
encoding cardiac filaments and sarcomeric proteins are gener- 
ally underexpressed (Fig. 2). Whether this is a cause or effect 
of the fewer, smaller cells is not possible to say from these 
data. As the cells begin to hypertrophy and throughout the rest 
of their lives, most of these genes are overexpressed. These 
findings demonstrate that the LV undergoes changes in gene 
expression that could be related to the pathophysiology of the 
hypertrophy (36). Interestingly, the switch of the Ttr gene from 
underexpressed in neonates to overexpressed in adults suggest 
stage-specific regulation. Ttr encodes a protein for exosome 
production, and high protein levels in serum have been previ- 
ously associated with lung cancer (6) and heart failure caused 
by accumulation of transthyretin amyloid fibrils in the heart 
(33). Additionally, the genes for cardiac alpha actin 1 (Actc1), 
caveolin-3 (Cav3), and four and a half LIM domains 2 (Fhl2) 
are upregulated in adult HHR and have been associated with 
cardiomyopathies in mice and humans (1, 28). Conversely, the 
persistent underexpression of Dsg2 suggests a constitutive 
difference between HHR and NHR that appears independent of 
the pathophysiological changes with  age. 
Interestingly, the majority of genes identified in HHR were 
not differentially expressed in the human samples (Fig. 2). This 
might reflect the nature of the diseases in the human repository 
that is composed primarily of samples from human idiopathic 
dilated cardiomyopathy rather than Mendelian human HCM. 
Furthermore, as we were unable to establish the age of the 
human samples, we cannot make direct comparisons to our rat 
data to further our understanding of gene expression patterns 
with the progression of  HCM. 
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EQ:1 Table 2. Predicted number of microRNA binding sites in or 
around the genes of  interest 
Region 
    Gene Promoter 5=UTR CDS 3=UTR  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CDS, coding DNA sequence; UTR, untranslated  region. 
 
To provide a comprehensive perspective about the processes 
involved in this pathology, we investigated DNA methylation 
profiles and SNPs published in GWAS data of the genes 
investigated. We were unable to find any relevant methylation 
data supporting further analyses, as the majority of the studies 
available were performed in a variety of cancers and only few 
and individual studies are available in CVD. However, two 
SNPs found in the GWAS data located in the cardiac troponin 
T2 (TNNT2) gene are associated with cardiac troponin-T levels 
and directly correlated to heart failure (40). These challenges in 
merging DNA, RNA, and epigenome data highlight the impor- 
tance of comprehensive studies publicly  available. 
Our findings provide evidence of the involvement of mono- 
genic genes in polygenic hypertrophic but might only account 
for part of the genes responsible for this disease. The preva- 
lence of rare variants and unidentified genes responsible for 
HCM are yet to be elucidated. Furthermore, the interaction 
mechanisms used by these genes deserve more attention and 
might aid professionals in determining diagnostics and prog- 
nosis of the disease. 
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